Pacira BioSciences, Inc. (PCRX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Pacira BioSciences, Inc. (PCRX) closed at USD 36.33 on 2026-10-15, a change of +72.9 % over the past year, with a market capitalization of USD 1.45B.

Pacira BioSciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pacira BioSciences, Inc. key figures

Previous close

USD 36.33 (2026-10-15)

1-year change

+72.9 %

Market cap

USD 1.45B

Enterprise value

USD 1.61B

P/E ratio (trailing)

103.83

P/E ratio (forward)

10.51

EPS (trailing)

0.35

EPS (forward)

3.46

PEG ratio

0.99

Price to book

2.15

Revenue growth

6.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.52

Employees

825

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pacira BioSciences, Inc. and compare it with other stocks.